111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.44%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while JHX stands at 217.04%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
Negative 10Y revenue/share CAGR while JHX stands at 179.03%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-3.41%
Negative 5Y CAGR while JHX stands at 74.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
33.22%
3Y revenue/share CAGR similar to JHX's 36.50%. Walter Schloss would assume both companies experience comparable short-term cycles.
26.97%
10Y OCF/share CAGR under 50% of JHX's 570.64%. Michael Burry would worry about a persistent underperformance in cash creation.
10.06%
Below 50% of JHX's 215.04%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-25.35%
Negative 3Y OCF/share CAGR while JHX stands at 204.01%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
518.86%
Net income/share CAGR above 1.5x JHX's 216.37% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
18.05%
Below 50% of JHX's 241.05%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
197.03%
Below 50% of JHX's 1193.65%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
120.25%
Below 50% of JHX's 8696.64%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
50.93%
Below 50% of JHX's 826.09%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
15.48%
Below 50% of JHX's 55.84%. Michael Burry suspects a serious short-term disadvantage in building book value.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
15.06%
AR growth well above JHX's 14.79%. Michael Burry fears inflated revenue or higher default risk in the near future.
5.72%
We show growth while JHX is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.72%
Asset growth 1.25-1.5x JHX's 3.98%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
5.72%
BV/share growth above 1.5x JHX's 3.57%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
7.11%
Debt growth far above JHX's 6.74%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
